

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7736529
<b>Application Number:</b>	09993647
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1010
<b>Title of Invention:</b>	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
<b>First Named Inventor/Applicant Name:</b>	Bernd Riedl
<b>Customer Number:</b>	23599
<b>Filer:</b>	Csaba Henter/Caitlin Sickler
<b>Filer Authorized By:</b>	Csaba Henter
<b>Attorney Docket Number:</b>	BAYER 18A
<b>Receipt Date:</b>	03-JUN-2010
<b>Filing Date:</b>	27-NOV-2001
<b>Time Stamp:</b>	11:50:06
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P414- InternationalSearchreportPCTU S0212064.pdf	95674 <small>63cbff0a414865243f1c7e97a2d9561c5dba52e7</small>	no	2

### Warnings:

### Information:

2	NPL Documents	P415- InternationalSearchreportPCTU S0212066.pdf	137005 4ed67045380065f977c0d520fa54ddf9a0b9 2c3b	no	2
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	P416- SupplementalSearchreportEP9 8963809.pdf	151257 96e64eac9ff3b347c7c84455298e05b6d0a6 dfe0	no	4
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	P417- SupplementalSearchreportEP9 8963810.pdf	152720 7cc2bebcc6b2d90a29ee5ec677d34031d81 654ef	no	4
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	P418- SupplementalSearchreportEP9 8965981.pdf	300498 9808c529a0d841ce907d594d0bf126155ff 9a62	no	8
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	P419- SupplementalSearchreportEP0 0903239.pdf	237147 fa7f767a2fb9676d528a4b3e6496373d842 d7c2	no	6
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	P420SupplementalSearchreportEP0905597.pdf	488268 2dc57a4951044256f6f9e72e590d73d1a7ae cd64	no	9
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	P421- BellgoreetalClinSciv100p5671. pdf	7467347 3aab4f82c3ee527cf1b22e89e271797703a4 33e6	no	9
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	P422-Belgore-et-al-Am-J- Hematology-v66-p59.pdf	2424891 8415213e3f0cf57f8e9c62dbdadcf2cccd61e 954	no	3
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	P423-Cuskun-et-al-Breast-v12- p104.pdf	6749231 5c8164380e34397ee5547172952d5bee18f 5a765	no	7
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	P424-Kaya-et-al-Respiratory-Med-v98-p632.pdf	4843314	no	5
			ede5774172642cb95cb56f8686ce15cc6f2d13e1		
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	P425-Kumar-et-al-Anticancer-Res-v22-n3-p1877.pdf	2463363	no	4
			30afc2a0b18e27047db7c9f75ad52d114882e80d		
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	P426-Pasieka-et-al-Cancer-Res-v162-p189.pdf	2906238	no	6
			9ec75caa05eb652e73b5f7a941fd67fdca337cc		
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	P427-Pegram-and-Reese-Sem-Oncology-v29-n3-Supp-11-p29.pdf	1565205	no	9
			aabe09eb08df034f988d1c21e83eb57cbd5cff79		
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	P428-Poon-et-al-Bri-J-Surgery-v91-p1354.pdf	6726170	no	7
			892721916c75af4bda98ed044b6bacc8dbb3d45c		
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	P429-Ria-et-al-Cancer-Ltts-v216-p103.pdf	3982386	no	5
			86d1622754e8b0b4b1ee3b07225ff333b23e9746		
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	P430-Secord-et-al-Gynecologic-Oncology-v94-n1-p74.pdf	1139926	no	6
			6b3af268b0219a7e861a4528b8a121d817cd7602		
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	P431-EnglishAbstractJP10306078.pdf	76850	no	2
			fbcf09e81c9bc97dd513e7935864944a9cdfab17		
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	P432-EnglishAbstractJP08301841.pdf	80180	no	2
			1f307f3474271433faffc694a477a844c59228bc3		
<b>Warnings:</b>					
<b>Information:</b>					

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**